- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/815 - Inhibiteurs de protéase provenant de sangsues, p. ex. hirudine, égline
Détention brevets de la classe C07K 14/815
Brevets de cette classe: 30
Historique des publications depuis 10 ans
|
4
|
2
|
3
|
0
|
1
|
0
|
1
|
0
|
1
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Chemical & Biopharmaceutical Laboratories of Patras S.A. | 28 |
2 |
| Lunan Pharmaceutical Group Corporation | 45 |
2 |
| Wuhan Yuanqi HE Sheng Technologiae Societas limitata | 3 |
2 |
| The General Hospital Corporation | 4871 |
1 |
| Ajinomoto Co., Inc. | 2281 |
1 |
| Baxter International Inc. | 1893 |
1 |
| Baxter Healthcare S.A. | 1396 |
1 |
| Cambridge Enterprise Limited | 1245 |
1 |
| CEM Corporation | 103 |
1 |
| Chengdu Shengnuo Tech Co., Ltd. | 3 |
1 |
| China Pharmaceutical University | 358 |
1 |
| Hybio Pharmaceutical Co., Ltd. | 121 |
1 |
| Kunming Institute of Zoology, Chinese Academy of Sciences | 42 |
1 |
| Kunming Longjin Pharmaceutical Co., Ltd. | 3 |
1 |
| Lonza Braine S.A. | 5 |
1 |
| Lonza Ltd. | 586 |
1 |
| NATCO Pharma Limited | 204 |
1 |
| National Research Council of Canada | 1548 |
1 |
| Novetide, Ltd. | 9 |
1 |
| Shandong New Time Pharmaceutical Co., Ltd. | 45 |
1 |
| Autres propriétaires | 7 |